Evidence map›Paper›PMID 40693184›Full record

ArticleNEJM catalyst innovations in care delivery2025

A Text Message Intervention to Minimize the Time Burden of Cancer Care.

Erin M Bange, Kerry Q Coughlin, Wenrui Li, Timothy J Brown, Daniel Ragusano, Eesha Balar, Dhivya Arasappan, Michelle Nnaji, Elliot Kim, Corey Alban and 18 more

Abstract read
In one paragraph

Article in NEJM catalyst innovations in care delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Erin M BangeFormer Medical Oncology Fellow, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
Kerry Q CoughlinAbramson Cancer Center, Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Wenrui LiFormer Postdoctoral Researcher, Department of Biostatistics, Epidemiology, & Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Timothy J BrownFormer Medical Oncology Fellow, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
Daniel RagusanoFormer Project Manager, Abramson Cancer Center, Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Eesha BalarFormer Research Assistant, Undergraduate Student, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Dhivya ArasappanTIME Project, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Michelle NnajiKeck School of Medicine, University of Southern California, Los Angeles, California, USA.
Elliot KimUndergraduate Student, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Corey AlbanOncology Unit, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sindhuja UppuluriUndergraduate Student, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Elizabeth MoriartyOncology and Genetics, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Tara BangeAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Lindsey ZinckAbramson Cancer Center and Cancer Service Line, Penn Medicine, Philadelphia, Pennsylvania, USA.
David SmithHospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Michael JosephsUniversity of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.
James J HarriganFormer Infectious Diseases Fellow, Hospital of the University of Pennsylvania, USA.
Roger B CohenDepartment of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Danielle ZubkaHospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Roy RosinFormer Chief Innovation Officer, Penn Medicine, Philadelphia, Pennsylvania, USA.
Mohan BalachandranCorporate Director, Penn Medicine, Philadelphia, Pennsylvania, USA.
Qi LongDirector, Biostatistics and Bioinformatics Core, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Andrea BilgerUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Lynn M SchuchterDirector, Tara Miller Melanoma Center, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Mira MamtaniAssociate Professor of Clinical Emergency Medicine, Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Lawrence N ShulmanAssociate Director for Special Projects of the Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Carmen E GuerraVice Chair of Diversity and Inclusion, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ronac MamtaniSection Chief, Genitourinary Cancers, Hematology/Oncology, Penn Medicine, Philadelphia, Pennsylvania, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
CANCER CLINICAL EPIDEMIOLOGY TRAINING GRANTT32CA009679 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Richard Aplenc, Karen Glanz · 1992 to 2026
$11.1M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016520NCI NIH HHS T32 CA009679
6 · The paper itself

Abstract

Patients with cancer spend considerable time commuting to, waiting for, and receiving health care. Patient-reported outcomes have been collected electronically to monitor patients for toxicity related to treatment, but, to the authors' knowledge, they have not been used as a strategy to minimize patients' time spent on cancer care by streamlining care delivery. Researchers at Penn Medicine set an objective to assess the effectiveness and implementation of a text message-based symptom reporting electronic triage (e-triage) versus usual care to minimize the time toxicity associated with ambulatory cancer care. The methods employed included a hybrid type 1 effectiveness-implementation, unblinded, randomized controlled trial and sequential mixed-methods study, which was conducted between December 1, 2021, and December 31, 2022, with a follow-up period of 3 months or three visits (whichever came first, but all within the 2-year window). Adult patients with solid tumors receiving single-agent immune checkpoint inhibitors (ICIs) with access to a text-messaging device were enrolled, with a target sample size of 176. The intervention was a symptom-based e-triage via mobile text messaging combined with routine laboratory testing. Participants in the e-triage group with normal bloodwork and no symptoms of drug toxicity on e-triage were eligible to fast-track to ICI infusion, bypassing the pretreatment office visit. The primary end point was total time per ambulatory encounter; secondary end points included wait time, ED or hospital visits, health-related quality of life, patient satisfaction, and implementation (reach and fidelity). Implementation readiness (acceptability, appropriateness, and feasibility), barriers, and facilitators were evaluated in a mixed-methods analysis among treating oncologists, measured via surveys and focus groups. For the study, 40 patients were randomly assigned, of which 31 were evaluated for the primary end point; the median age among the 40 participants was 67.5 years of age (interquartile range 59.5-71.5 years of age), 80.0% were male, and 84.6% were white. Those randomly assigned to the e-triage group of the pilot randomized controlled trial (n=19, n=16 evaluable) had an average of 66.0 minutes less total time (95% confidence interval [CI], -123.7 to -8.08 minutes;

Identifiers

PMID40693184
PMCPMC12276887

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.